Lineage Cell Therapeutics (LCTX) News Today $0.59 +0.02 (+2.80%) As of 01/17/2025 04:10 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Sees Large Growth in Short InterestLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 26,030,000 shares, an increase of 13.5% from the December 15th total of 22,940,000 shares. Based on an average trading volume of 2,170,000 shares, the days-to-cover ratio is currently 12.0 days.January 18 at 5:20 AM | marketbeat.comMaxim Group Lowers Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target to $3.00January 12, 2025 | americanbankingnews.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given New $3.00 Price Target at Maxim GroupMaxim Group reduced their price target on Lineage Cell Therapeutics from $5.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday.January 10, 2025 | marketbeat.comLineage Cell Therapeutics Issues Letter to StockholdersJanuary 6, 2025 | finance.yahoo.comThe Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 ExpertsJanuary 4, 2025 | benzinga.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given "Buy" Rating at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a research report on Friday.January 3, 2025 | marketbeat.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1% - Here's What HappenedLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Down 1% - Here's WhyDecember 28, 2024 | marketbeat.comLineage Cell Therapeutics, Inc. (LCTX.TA)December 10, 2024 | finance.yahoo.comLineage Cell Therapeutics FY2024 EPS Lifted by HC WainwrightLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Analysts at HC Wainwright upped their FY2024 EPS estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Wednesday, December 4th. HC Wainwright analyst J. Pantginis now anticipates that the comDecember 6, 2024 | marketbeat.comIs Lineage Cell Therapeutics (LCTX) the Best New Pick in Brad Gerstner’s Portfolio?December 1, 2024 | insidermonkey.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) CEO Purchases $24,000.00 in StockNovember 23, 2024 | insidertrades.comBrian M. Culley Acquires 40,000 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) StockLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) CEO Brian M. Culley purchased 40,000 shares of the firm's stock in a transaction on Thursday, November 21st. The stock was bought at an average cost of $0.60 per share, for a total transaction of $24,000.00. Following the completion of the purchase, the chief executive officer now directly owns 194,842 shares in the company, valued at approximately $116,905.20. This trade represents a 25.83 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.November 22, 2024 | marketbeat.comLineage Therap Announces $66 Million Direct OfferingNovember 21, 2024 | markets.businessinsider.comLineage Cell Therapeutics FY2024 EPS Raised by Cantor FitzgeraldLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Analysts at Cantor Fitzgerald upped their FY2024 EPS estimates for Lineage Cell Therapeutics in a report issued on Monday, November 18th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per sNovember 21, 2024 | marketbeat.comLineage Cell price target lowered to $2 from $3 at D. Boral CapitalNovember 20, 2024 | markets.businessinsider.comLineage Cell Therapeutics tumbles after pricing $66M securities offeringNovember 20, 2024 | msn.comLineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct OfferingNovember 20, 2024 | finance.yahoo.comD. Boral Capital Initiates Coverage of Lineage Cell Therapeutics (LCTX) with Buy RecommendationNovember 19, 2024 | msn.comLineage Cell Therapeutics initiated with a Buy at D. Boral CapitalNovember 18, 2024 | markets.businessinsider.comLineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...November 15, 2024 | uk.finance.yahoo.comLineage Cell Therapeutics Reports Q3 2024 HighlightsNovember 15, 2024 | markets.businessinsider.comLineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comLineage Cell Therapeutics's Earnings OutlookNovember 13, 2024 | benzinga.comLineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare SummitOctober 14, 2024 | businesswire.comLogos Global Management LP Decreases Stock Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)Logos Global Management LP cut its stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 24.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,700,000 shares of theOctober 1, 2024 | marketbeat.comOpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International SymposiumSeptember 25, 2024 | businesswire.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) is Raffles Associates LP's 8th Largest PositionRaffles Associates LP increased its stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 35.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,357,78September 24, 2024 | marketbeat.comLineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology WorkshopSeptember 18, 2024 | finance.yahoo.comMBX Biosciences Inc.September 17, 2024 | money.usnews.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Short Interest Up 6.5% in AugustLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 15,510,000 shares, an increase of 6.5% from the July 31st total of 14,560,000 shares. Based on an average daily trading volume, of 796,300 shares, the days-to-cover ratio is presently 19.5 days.September 2, 2024 | marketbeat.comCraig-Hallum Initiates Coverage of Lineage Cell Therapeutics (LCTX) with Buy RecommendationAugust 21, 2024 | msn.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from Analysts at Craig HallumCraig Hallum started coverage on Lineage Cell Therapeutics in a report on Tuesday. They issued a "buy" rating and a $4.00 price target on the stock.August 20, 2024 | marketbeat.comBuy Rating Affirmed for Lineage Cell Therapeutics Amid Strategic Partnerships and Pipeline ProgressAugust 13, 2024 | markets.businessinsider.comLineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceAugust 13, 2024 | finance.yahoo.comLineage Cell Therapeutics: A Buy Rating Amidst Financial Stability and Promising Clinical ProgressAugust 10, 2024 | markets.businessinsider.comLineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | seekingalpha.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Short Interest Up 12.7% in JulyLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) was the target of a large growth in short interest in July. As of July 15th, there was short interest totalling 14,560,000 shares, a growth of 12.7% from the June 30th total of 12,920,000 shares. Based on an average daily trading volume, of 950,200 shares, the days-to-cover ratio is presently 15.3 days.July 29, 2024 | marketbeat.comBuy Rating Affirmed for Lineage Cell Therapeutics on Promising OpRegen Trials and Strategic Roche PartnershipJuly 26, 2024 | markets.businessinsider.comLineage Cell Therapeutics, Inc. (LCTX)July 23, 2024 | finance.yahoo.comArtiva Biotherapeutics IncJuly 22, 2024 | money.usnews.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Down 1%Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Down 1%July 20, 2024 | marketbeat.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Down 1.5%Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Down 1.5%June 27, 2024 | marketbeat.comLineage to Present at 2024 BIO International ConventionMay 30, 2024 | businesswire.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) CEO Acquires $10,500.00 in StockMay 29, 2024 | insidertrades.comLineage Cell Therapeutics Inc.May 26, 2024 | barrons.comLineage Announces Updates to 2nd Annual Spinal Cord Injury Investor SymposiumMay 21, 2024 | finance.yahoo.comBuy Rating on Lineage Therapeutics Backed by Roche Collaboration and Solid FinancialsMay 14, 2024 | markets.businessinsider.comQ1 2024 Lineage Cell Therapeutics Inc Earnings CallMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue DeclinesMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.com Get Lineage Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address LCTX Media Mentions By Week LCTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LCTX News Sentiment▼0.460.46▲Average Medical News Sentiment LCTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LCTX Articles This Week▼11▲LCTX Articles Average Week Get Lineage Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Annexon News Pharvaris News Keros Therapeutics News Mereo BioPharma Group News Rapport Therapeutics News Ginkgo Bioworks News Entrada Therapeutics News Tourmaline Bio News Oruka Therapeutics News Xeris Biopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:LCTX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lineage Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LCTX Stock Alerts